BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Egami S, Kawazoe H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Fukunaga K, Yamaguchi M, Nakamura T. Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study. Front Oncol 2021;11:618570. [PMID: 34123782 DOI: 10.3389/fonc.2021.618570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, Torrego N, Campillo-Calatayud A, Elejalde I, Kochan G, Escors D. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events. Cancers (Basel) 2023;15. [PMID: 36900420 DOI: 10.3390/cancers15051629] [Reference Citation Analysis]
2 Zhou J, Du Z, Fu J, Yi X. Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis. Front Immunol 2023;14:1117447. [PMID: 36960068 DOI: 10.3389/fimmu.2023.1117447] [Reference Citation Analysis]
3 Wan L, Wu C, Luo S, Xie X. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors. Dis Markers 2022;2022:3610038. [PMID: 36590752 DOI: 10.1155/2022/3610038] [Reference Citation Analysis]
4 Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Kawasaki T, Furukawa T, Nakamura T. Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study. Front Oncol 2022;12:898150. [DOI: 10.3389/fonc.2022.898150] [Reference Citation Analysis]
5 Odeny TA, Lurain K, Strauss J, Fling SP, Sharon E, Wright A, Martinez-picado J, Moran T, Gulley JL, Gonzalez-cao M, Uldrick TS, Yarchoan R, Ramaswami R. Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. J Immunother Cancer 2022;10:e005128. [DOI: 10.1136/jitc-2022-005128] [Reference Citation Analysis]
6 Cho Y, Kim Y, Chamseddine I, Lee WH, Kim HR, Lee IJ, Hong MH, Cho BC, Lee CG, Cho S, Kim JS, Yoon HI, Grassberger C. Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. Radiother Oncol 2022;168:1-7. [PMID: 35033601 DOI: 10.1016/j.radonc.2022.01.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
7 Ogiwara T, Kawazoe H, Egami S, Hashimoto H, Saito Y, Sakiyama N, Ohe Y, Yamaguchi M, Furukawa T, Hara A, Hiraga Y, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T. Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study. Front Oncol 2021;11:770268. [PMID: 34820333 DOI: 10.3389/fonc.2021.770268] [Cited by in F6Publishing: 1] [Reference Citation Analysis]